Study to Evaluate the Efficacy and Safety of Deuruxolitinib in Japanese Adults With Severe Alopecia Areata

Phase 3 Recruiting 78 enrolled Sun Pharma Japan Limited

RandomizedParallel-groupQuadruple-blindTreatment

Summary

This study evaluates the efficacy and safety of deuruxolitinib in Japanese Adults between 18 and 65 years of age who have 50% or greater scalp hair loss.

Timeline

Start: 2026-06-19
Primary completion: 2028-02
Completion: 2028-09

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	CTP-543	Unknown	8 mg	Oral

Study to Evaluate the Efficacy and Safety of Deuruxolitinib in Japanese Adults With Severe Alopecia Areata

Summary

Timeline

Drugs

Indications